

## Ohtuvayre<sup>™</sup> (ensifentrine) – New drug approval

- On June 26, 2024, <u>Verona Pharma announced</u> the FDA approval of <u>Ohtuvayre (ensifentrine)</u>, for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients.
- Approximately 8.6 million people in the U.S. are treated chronically for COPD.
- Ohtuvayre is a first-in-class selective dual inhibitor of the enzymes phosphodiesterase 3 and phosphodiesterase 4 (PDE3 and PDE4). Inhibition of both enzymes is believed to have a bronchodilator and non-steroidal anti-inflammatory effect.
- The efficacy of Ohtuvayre was established in two randomized, double-blind, placebo-controlled studies (ENHANCE-1 and ENHANCE-2) in a total of 1,553 adults with moderate to severe COPD. In both studies, patients received Ohtuvayre or placebo. The primary endpoint wasaverage forced expiratory volume in the first second (FEV<sub>1</sub>) area under the curve (AUC)0–12 h post dose at 12 weeks.
  - In ENHANCE-1, the least squares (LS) mean change from baseline in FEV<sub>1</sub> AUC<sub>0-12h</sub> at week 12 was 61 mL with Ohtuvayre vs. -26 mL with placebo (difference 87, 95% CI: 55, 118; p < 0.0001).
  - In ENHANCE-2, the LS mean change from baseline in FEV<sub>1</sub> AUC<sub>0-12h</sub> at week 12 was 48 mL with Ohtuvayre vs. -46 mL with placebo (difference 94, 95% CI: 65, 124; p < 0.0001).</li>
- Warnings and precautions for Ohtuvayre include acute episodes of bronchospasm, paradoxical bronchospasm, and psychiatric events including suicidality.
- The most common adverse reactions (≥ 1% and more common than placebo) with Ohtuvayre use were back pain, hypertension, urinary tract infection, and diarrhea.
- The recommended dosage of Ohtuvayre is 3 mg (one unit-dose ampule) twice daily, once in the morning and once in the evening, administered by oral inhalation using a standard jet nebulizer with a mouthpiece.
- Verona Pharma plans to launch Ohtuvayre in the third quarter 2024. Ohtuvayre will be available as a 3 mg/2.5 mL aqueous suspension in unit-dose ampules.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.